secwatch.observer — SEC 8-K summary
======================================

Issuer:     Autolus Therapeutics plc (AUTL)
CIK:        0001730463
Form:       8-K
Filed at:   2026-01-26T23:59:59+00:00
Accession:  0001730463-26-000019
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Autolus enters 10-year lentiviral vector supply deal with AGC Biologics
-----------------------------------------------------------------------

- Master Service Agreement with AGC Biologics for lentiviral vector, critical for CAR-T production.
- Minimum purchase: 14 batches in first 2 years; EUR 25 million over subsequent 5 years.
- AGC granted first right to negotiate manufacturing of obe-cel (obecabtagene autoleucel).
- 10-year fixed term, non-exclusive; Autolus can terminate with certain fees, either party for default.
- Agreement replaces prior arrangement; individual work orders govern specific projects.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1730463/000173046326000019/0001730463-26-000019-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1730463/000173046326000019/autl-20260121.htm
  HTML page:      https://secwatch.observer/filing/0001730463-26-000019

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer